How effective is Venetoclax?

Research shows that when Venetoclax is used alone to treat chronic lymphocytic leukemia (CLL), cancer cells are partially or completely eliminated in most patients. In a major study, 75% of 107 patients previously treated for CLL and 17p deletion had a partial or complete response to venetoclax. In another study of 127 patients with 17p deletions or TP53 mutations, the response rate was 70%.

The third study, which looked at 389 patients with CLL who had received at least one prior treatment, showed that patients who received venetoclax plus intravenous rituximab lived longer without their disease getting worse (progression-free survival). Another study involving 432 CLL patients who had not been previously treated for the disease found that patients who received venetoclax versus intravenous obinutuzumab lived longer without worsening of their disease.

A study involving431 patients with acute myeloid leukemia (AML) who had not been previously treated for the disease found that 65% of patients who received venetoclax plus azacitidine had no signs of the disease (complete response), with or without recovery of their blood cells. Patients who received venetoclax plus intravenous azacitidine lived an average of 15 months.

The original drug of Venacla has been launched in China and can be found in the Category B medical insurance catalog. The specificationsThe price of 100mg*14 tablets per box may be around 5,000 RMB. The Turkish version of the original drug Venekra, which is marketed overseas, has a specification of 100mg*112 tablets and the price per box is around RMB 10,000 (the price may fluctuate due to the exchange rate), which is even more expensive. Cheaper generic drugs are also sold overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs. The price of a box of 100mg*120 tablets produced by a Bangladeshi pharmaceutical factory is around RMB 4,000 (prices may fluctuate due to exchange rates).